Maximizing Anti-Tumor Response: Targeting the RAS/MAPK Pathway Using a RASAgnostic Approach

Time: 3:00 pm
day: Day One Track B PM


  • Targeting the RAS binding domain with Rigosertib to inhibit binding of multiple downstream proteins in the RAS/MAPK pathway leads to effective cancer treatment
  • Transforming cold tumors to hot tumors with Rigosertib by upregulating neoantigen presentation increases immune system involvement and results in a better anti-cancer response
  • Exploring combinations with Immune Checkpoint Inhibitors (ICIs) offers the potential for a moreveffective response to cancer